CRDF Stock: Cardiff Oncology to Proceed With Phase 2 Study

Cardiff Oncology CRDF Stock News

Cardiff Oncology Inc (NASDAQ: CRDF) is making its way for the top in the market this morning, and for good reason. The company announced that it received a Study May Proceed letter from the United States Food and Drug Administration (FDA). Here’s what’s going on: Skip to What You Want to Read Cardiff Oncology Announces … Read more